DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes

Bibliography

• Cech TR, Zaug AJ, Grabowski PJ. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 1981;27:487-96
   PubMed Web of Science ®Google Scholar
• Guerrier-Takada C, Gardiner K, Marsh T, et al. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983;35:849-57
   PubMed Web of Science ®Google Scholar
• Chartrand P, Harvey SC, Ferbeyre G, et al. An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain. Nucleic Acids Res 1995;23:4092-6
   PubMed Web of Science ®Google Scholar
• Achenbach JC, Chiuman W, Cruz RP, Li Y. DNAzymes: from creation in vitro to application in vivo. Curr Pharm Biotechnol 2004;5:321-36
   PubMed Web of Science ®Google Scholar
• Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997;94:4262-6
   PubMed Web of Science ®Google Scholar
• Kurreck J, Bieber B, Jahnel R, Erdmann VA. Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem 2002;277:7099-107
   PubMed Web of Science ®Google Scholar
• Santiago FS, Lowe HC, Kavurma MM, et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999;5:1264-9
   PubMed Web of Science ®Google Scholar
• Cieslak M, Szymanski J, Adamiak RW, Cierniewski CS. Structural rearrangements of the 10-23 DNAzyme to beta 3 integrin subunit mRNA induced by cations and their relations to the catalytic activity. J Biol Chem 2003;278:47987-96
   Google Scholar
• Cieslak M, Niewiarowska J, Nawrot M, et al. DNAzymes to beta 1 and beta 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem 2002;277:6779-87
   PubMed Web of Science ®Google Scholar
• Clawson GA, Miranda GQ, Sivarajah A, et al. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA. Gene Ther 2004;11:1331-41
   PubMed Web of Science ®Google Scholar
• Ackermann JM, Kanugula S, Pegg AE. DNAzyme-mediated silencing of ornithine decarboxylase. Biochemistry 2005;44:2143-52
   PubMed Web of Science ®Google Scholar
• Goila R, Banerjea AC. Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme. FEBS Lett 1998;436:233-8
   PubMed Web of Science ®Google Scholar
• Yen L, Strittmatter SM, Kalb RG. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann Neurol 1999;46:366-73
   PubMed Web of Science ®Google Scholar
• Chen F, Li Z, Wang R, et al. Inhibition of ampicillin-resistant bacteria by novel mono-DNAzymes and di-DNAzyme targeted to beta-lactamase mRNA. Oligonucleotides 2004;14:80-9
   PubMed Web of Science ®Google Scholar
• Xie YY, Zhao XD, Jiang LP, et al. Inhibition of respiratory syncytial virus in cultured cells by nucleocapsid gene targeted deoxyribozyme (DNAzyme). Antiviral Res 2006;71:31-41
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Vrati S. DNAzyme-mediated Inhibition of Japanese Encephalitis Virus Replication in Mouse Brain. Mol Ther 2007;15:1593-9
   PubMed Web of Science ®Google Scholar
• Roy S, Gupta N, Subramanian N, et al. Sequence-specific cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication. J Gen Virol 2008;89:1579-86
   PubMed Web of Science ®Google Scholar
• Qu Y, Zhang L, Mao M, et al. Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer. Cancer Gene Ther 2008;15:517-25
   PubMed Web of Science ®Google Scholar
• Kumar D, Chaudhury I, Kar P, Das RH. Site-specific cleavage of HCV genomic RNA and its cloned core and NS5B genes by DNAzyme. J Gastroenterol Hepatol 2009;24:872-8
   PubMed Web of Science ®Google Scholar
• Fokina AA, Meschaninova MI, Durfort T, et al. Targeting insulin-like growth factor I with 10-23 DNAzymes: 2’-O-methyl modifications in the catalytic core enhance mRNA cleavage. Biochemistry 2012;51:2181-91
   PubMed Web of Science ®Google Scholar
• Kumar B, Kumar P, Rajput R, et al. Sequence-specific cleavage of BM2 gene transcript of influenza B virus by 10-23 catalytic motif containing DNA enzymes significantly inhibits viral RNA translation and replication. Nucleic Acid Ther 2013;23:355-62
   PubMedGoogle Scholar
• Juliano RL, Ming X, Nakagawa O. The chemistry and biology of oligonucleotide conjugates. Acc Chem Res 2012;45:1067-76
   PubMed Web of Science ®Google Scholar
• Santoro SW, Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 1998;37:13330-42
   PubMed Web of Science ®Google Scholar
• Abdelgany A, Ealing J, Wood M, Beeson D. Selective DNAzyme-mediated cleavage of AChR mutant transcripts by targeting the mutation site or through mismatches in the binding arm. J RNAi Gene Silencing 2005;1:32-7
   PubMedGoogle Scholar
• Wang TH, Li WT, Yu SH, Au LC. The use of 10-23 DNAzyme to selectively destroy the allele of mRNA with a unique purine-pyrimidine dinucleotide. Oligonucleotides 2008;18:295-9
   PubMed Web of Science ®Google Scholar
• Wu Y, Yu L, McMahon R, et al. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther 1999;10:2847-57
   PubMed Web of Science ®Google Scholar
• Warashina M, Kuwabara T, Nakamatsu Y, Taira K. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome. Chem Biol 1999;6:237-50
   PubMed Web of Science ®Google Scholar
• Kabuli M, Yin JA, Tobal K. Targeting PML/RARalpha transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells. Hematol J 2004;5:426-33
   PubMedGoogle Scholar
• Choi WH, Choi BR, Kim JH, et al. Design and kinetic analysis of hammerhead ribozyme and DNAzyme that specifically cleave TEL-AML1 chimeric mRNA. Biochem Biophys Res Commun 2008;374:169-74
   PubMed Web of Science ®Google Scholar
• Kim JE, Yoon S, Choi BR, et al. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells. leukaemia 2013;27:1650-8
   PubMed Web of Science ®Google Scholar
• Cairns MJ, King A, Sun LQ. Nucleic acid mutation analysis using catalytic DNA. Nucleic Acids Res 2000;28:E9
   PubMedGoogle Scholar
• Cai H, Santiago FS, Prado-Lourenco L, et al. DNAzyme targeting c-jun suppresses skin cancer growth. Sci Transl Med 2012;4:139ra182
   Google Scholar
• Dicke T, Pali-Scholl I, Kaufmann A, et al. Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes. Nucleic Acid Ther 2012;22:117-26
   PubMed Web of Science ®Google Scholar
• Fuhst R, Runge F, Buschmann J, et al. Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure. Pulm Pharmacol Ther 2013;26:281-9
   PubMed Web of Science ®Google Scholar
• Hallett MA, Dalal P, Sweatman TW, Pourmotabbed T. The Distribution, Clearance, and Safety of an Anti-MMP-9 DNAzyme in Normal and MMTV-PyMT Transgenic Mice. Nucleic Acid Ther 2013;23:379-88
   Google Scholar
• Shen L, Zhou Q, Wang Y, et al. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme. Mol Med 2013;19:377-86
   PubMed Web of Science ®Google Scholar
• Rivory L, Tucker C, King A, et al. The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. Oligonucleotides 2006;16:297-312
   PubMed Web of Science ®Google Scholar
• Goodchild A, King A, Gozar MM, et al. Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res 2007;35:4562-72
   PubMed Web of Science ®Google Scholar
• Gozar MM, Goodchild A, Passioura T, et al. Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death. Oligonucleotides 2008;18:257-68
   PubMed Web of Science ®Google Scholar
• Zhang G, Dass CR, Sumithran E, et al. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004;96:683-96
   PubMed Web of Science ®Google Scholar
• Khachigian LM, Fahmy RG, Zhang G, et al. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J Biol Chem 2002;277:22985-91
   PubMed Web of Science ®Google Scholar
• Chan CW, Kaplan W, Parish CR, Khachigian LM. Reduced retinal microvascular density, improved forepaw reach, comparative microarray and gene set enrichment analysis with c-jun targeting DNA enzyme. PLoS One 2012;7:e39160
   PubMed Web of Science ®Google Scholar
• Dass CR, Choong PF. Sequence-related off-target effect of Dz13 against human tumor cells and safety in adult and fetal mice following systemic administration. Oligonucleotides 2010;20:51-60
   PubMed Web of Science ®Google Scholar
• Dass CR, Tan ML, Galloway SJ, Choong PF. Dz13 induces a cytotoxic stress response with upregulation of E2F1 in tumor cells metastasizing to or from bone. Oligonucleotides 2010;20:79-91
   PubMed Web of Science ®Google Scholar
• Dass CR, Galloway SJ, Choong PF. Dz13, a c-jun DNAzyme, is a potent inducer of caspase-2 activation. Oligonucleotides 2010;20:137-46
   PubMed Web of Science ®Google Scholar
• Kim SH, Dass CR. Induction of caspase-2 activation by a DNA enzyme evokes tumor cell apoptosis. DNA Cell Biol 2012;31:1-7
   PubMed Web of Science ®Google Scholar
• Sioud M, Leirdal M. Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application. J Mol Biol 2000;296:937-47
   PubMed Web of Science ®Google Scholar
• Reyes-Gutierrez P, Alvarez-Salas LM. Cleavage of HPV-16 E6/E7 mRNA mediated by modified 10-23 deoxyribozymes. Oligonucleotides 2009;19:233-42
   PubMed Web of Science ®Google Scholar
• Wiktorska M, Sacewicz-Hofman I, Stasikowska-Kanicka O, et al. Distinct inhibitory efficiency of siRNAs and DNAzymes to beta1 integrin subunit in blocking tumor growth. Acta Biochim Pol 2013;60:77-82
   PubMed Web of Science ®Google Scholar
• Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003;270:1628-44
   PubMedGoogle Scholar
• Schubert S, Gul DC, Grunert HP, et al. RNA cleaving ‘10-23’ DNAzymes with enhanced stability and activity. Nucleic Acids Res 2003;31:5982-92
   PubMed Web of Science ®Google Scholar
• Tan ML, Choong PF, Dass CR. DNAzyme delivery systems: getting past first base. Expert Opin Drug Deliv 2009;6:127-38
   PubMed Web of Science ®Google Scholar
• Chan CW, Khachigian LM. DNAzyme delivery approaches in biological settings. Curr Med Chem 2013;20:3448-55
   PubMed Web of Science ®Google Scholar
• Basu S, Sriram B, Goila R, Banerjea AC. Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function. Antiviral Res 2000;46:125-34
   PubMed Web of Science ®Google Scholar
• Dash BC, Harikrishnan TA, Goila R, et al. Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated cell fusion. FEBS Lett 1998;431:395-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Xu Y, Ling H, Hattori T. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. FEBS Lett 1999;458:151-6
   PubMed Web of Science ®Google Scholar
• Sugiyama R, Hayafune M, Habu Y, et al. HIV-1 RT-dependent DNAzyme expression inhibits HIV-1 replication without the emergence of escape viruses. Nucleic Acids Res 2011;39:589-98
   PubMed Web of Science ®Google Scholar
• Unwalla H, Banerjea AC. Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression. Antiviral Res 2001;51:127-39
   PubMed Web of Science ®Google Scholar
• Unwalla H, Banerjea AC. Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA. Biochem J 2001;357:147-55
   PubMed Web of Science ®Google Scholar
• Unwalla H, Chakraborti S, Sood V, et al. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme. Antiviral Res 2006;72:134-44
   PubMed Web of Science ®Google Scholar
• Sood V, Unwalla H, Gupta N, et al. Potent knock down of HIV-1 replication by targeting HIV-1 Tat/Rev RNA sequences synergistically with catalytic RNA and DNA. Aids 2007;21:31-40
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Banerjea AC. Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates. Mol Ther 2003;7:817-26
   PubMed Web of Science ®Google Scholar
• Dash BC, Banerjea AC. Sequence-specific cleavage activities of DNA enzymes targeted against HIV-1 Gag and Nef regions. Oligonucleotides 2004;14:41-7
   PubMed Web of Science ®Google Scholar
• Singh N, Ranjan A, Sur S, et al. Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme. J Biosci 2012;37:493-502
   PubMed Web of Science ®Google Scholar
• Bano AS, Gupta N, Sharma Y, et al. HIV-1 VprB and C RNA cleavage by potent 10-23 DNAzymes that also cause reversal of G2 cell cycle arrest mediated by Vpr genes. Oligonucleotides 2007;17:465-72
   PubMed Web of Science ®Google Scholar
• Goila R, Banerjea AC. Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochem J 2001;353:701-8
   PubMed Web of Science ®Google Scholar
• Hou W, Ni Q, Wo J, et al. Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes. Antiviral Res 2006;72:190-6
   PubMed Web of Science ®Google Scholar
• Wo JE, Wu XL, Zhou LF, et al. Effective inhibition of expression of hepatitis B virus genes by DNAzymes. World J Gastroenterol 2005;11:3504-7
   PubMed Web of Science ®Google Scholar
• Hou W, Wo JE, Li MW, Liu KZ. In vitro cleavage of hepatitis B virus C mRNA by 10-23 DNA enzyme. Hepatobiliary Pancreat Dis Int 2005;4:573-6
   PubMedGoogle Scholar
• Asahina Y, Ito Y, Wu CH, Wu GY. DNA ribonucleases that are active against intracellular hepatitis B viral RNA targets. Hepatology 1998;28:547-54
   PubMed Web of Science ®Google Scholar
• Oketani M, Asahina Y, Wu CH, Wu GY. Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease. J Hepatol 1999;31:628-34
   PubMed Web of Science ®Google Scholar
• Trepanier J, Tanner JE, Momparler RL, et al. Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J Viral Hepat 2006;13:131-8
   PubMed Web of Science ®Google Scholar
• Lee B, Kim KB, Oh S, et al. Suppression of hepatitis C virus genome replication in cells with RNA-cleaving DNA enzymes and short-hairpin RNA. Oligonucleotides 2010;20:285-96
   PubMed Web of Science ®Google Scholar
• Ryoo SR, Jang H, Kim KS, et al. Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown. Biomaterials 2012;33:2754-61
   PubMed Web of Science ®Google Scholar
• Toyoda T, Imamura Y, Takaku H, et al. Inhibition of influenza virus replication in cultured cells by RNA-cleaving DNA enzyme. FEBS Lett 2000;481:113-16
   PubMed Web of Science ®Google Scholar
• Takahashi H, Hamazaki H, Habu Y, et al. A new modified DNA enzyme that targets influenza virus A mRNA inhibits viral infection in cultured cells. FEBS Lett 2004;560:69-74
   PubMed Web of Science ®Google Scholar
• Kumar B, Khanna M, Kumar P, et al. Nucleic acid-mediated cleavage of M1 gene of influenza A virus is significantly augmented by antisense molecules targeted to hybridize close to the cleavage site. Mol Biotechnol 2012;51:27-36
   PubMed Web of Science ®Google Scholar
• Zhou J, Yang XQ, Xie YY, et al. Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme DZ1133 in mice. Virus Res 2007;130:241-8
   PubMed Web of Science ®Google Scholar
• Wu S, Xu J, Liu J, et al. An efficient RNA-cleaving DNA enzyme can specifically target the 5’-untranslated region of severe acute respiratory syndrome associated coronavirus (SARS-CoV). J Gene Med 2007;9:1080-6
   PubMed Web of Science ®Google Scholar
• Yang L, Lu Z, Ma X, et al. A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBV LMP-1 gene. Molecules 2010;15:6127-39
   PubMed Web of Science ®Google Scholar
• Lu ZX, Ye M, Yan GR, et al. Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther 2005;12:647-54
   PubMed Web of Science ®Google Scholar
• Lu ZX, Ma XQ, Yang LF, et al. DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett 2008;265:226-38
   PubMed Web of Science ®Google Scholar
• Ma X, Xu Z, Yang L, et al. EBV-LMP1-targeted DNAzyme induces DNA damage and causes cell cycle arrest in LMP1-positive nasopharyngeal carcinoma cells. Int J Oncol 2013;43:1541-8
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang L, Huang S, et al. Delivery system for DNAzymes using arginine-modified hydroxyapatite nanoparticles for therapeutic application in a nasopharyngeal carcinoma model. Int J Nanomedicine 2013;8:3107-18
   PubMed Web of Science ®Google Scholar
• Ke X, Yang YC, Hong SL. EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model. Med Oncol 2011;28(Suppl 1):S326-32
   PubMedGoogle Scholar
• Hou Z, Meng JR, Zhao JR, et al. Inhibition of beta-lactamase-mediated oxacillin resistance in Staphylococcus aureus by a deoxyribozyme. Acta Pharmacol Sin 2007;28:1775-82
   PubMed Web of Science ®Google Scholar
• Hou Z, Meng JR, Niu C, et al. Restoration of antibiotic susceptibility in methicillin-resistant Staphylococcus aureus by targeting mecR1 with a phosphorothioate deoxyribozyme. Clin Exp Pharmacol Physiol 2007;34:1160-4
   PubMed Web of Science ®Google Scholar
• Li J, Zhu D, Yi Z, et al. DNAzymes targeting the icl gene inhibit ICL expression and decrease Mycobacterium tuberculosis survival in macrophages. Oligonucleotides 2005;15:215-22
   PubMed Web of Science ®Google Scholar
• Fahmy RG, Dass CR, Sun LQ, et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003;9:1026-32
   PubMed Web of Science ®Google Scholar
• Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res 2004;32:3065-9
   PubMed Web of Science ®Google Scholar
• Dass CR, Friedhuber AM, Khachigian LM, et al. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J Microencapsul 2008;25:421-5
   PubMed Web of Science ®Google Scholar
• Zhang G, Luo X, Sumithran E, et al. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 2006;25:7260-6
   PubMed Web of Science ®Google Scholar
• Dass CR, Friedhuber AM, Khachigian LM, et al. Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol Ther 2008;7:1033-6
   PubMed Web of Science ®Google Scholar
• Dass CR, Khachigian LM, Choong PF. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther 2008;7:1909-12
   PubMed Web of Science ®Google Scholar
• Dass CR, Galloway SJ, Clark JC, et al. Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther 2008;7:1297-301
   PubMed Web of Science ®Google Scholar
• Cho EA, Moloney FJ, Cai H, et al. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet 2013;381:1835-43
   PubMed Web of Science ®Google Scholar
• Zhang L, Gasper WJ, Stass SA, et al. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res 2002;62:5463-9
   PubMed Web of Science ®Google Scholar
• Liu C, Cheng R, Sun LQ, Tien P. Suppression of platelet-type 12-lipoxygenase activity in human erythroleukaemia cells by an RNA-cleaving DNAzyme. Biochem Biophys Res Commun 2001;284:1077-82
   PubMed Web of Science ®Google Scholar
• Niewiarowska J, Sacewicz I, Wiktorska M, et al. DNAzymes to mouse beta1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth. Cancer Gene Ther 2009;16:713-22
   PubMed Web of Science ®Google Scholar
• Wiktorska M, Papiewska-Pajak I, Okruszek A, et al. DNAzyme as an efficient tool to modulate invasiveness of human carcinoma cells. Acta Biochim Pol 2010;57:269-75
   PubMed Web of Science ®Google Scholar
• de Bock CE, Lin Z, Itoh T, et al. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J 2005;272:3572-82
   PubMed Web of Science ®Google Scholar
• Yang L, Zeng W, Li D, Zhou R. Inhibition of cell proliferation, migration and invasion by DNAzyme targeting MMP-9 in A549 cells. Oncol Rep 2009;22:121-6
   PubMed Web of Science ®Google Scholar
• Hallett MA, Teng B, Hasegawa H, et al. Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer. Breast Cancer Res 2013;15:R12
   PubMed Web of Science ®Google Scholar
• Robaldo L, Izzo F, Dellafiore M, et al. Influence of conformationally restricted pyrimidines on the activity of 10-23 DNAzymes. Bioorg Med Chem 2012;20:2581-6
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhao H, Luo F, et al. IGF-II inhibitory DNAzymes inhibit the invasion and migration of hepatocarcinoma cells. Biotechnol Lett 2011;33:911-17
   PubMed Web of Science ®Google Scholar
• Zhang M, Drummen GP, Luo S. Anti-insulin-like growth factor-IIP3 DNAzymes inhibit cell proliferation and induce caspase-dependent apoptosis in human hepatocarcinoma cell lines. Drug Des Devel Ther 2013;7:1089-102
   PubMed Web of Science ®Google Scholar
• Liang Z, Wei S, Guan J, et al. DNAzyme-mediated cleavage of survivin mRNA and inhibition of the growth of PANC-1 cells. J Gastroenterol Hepatol 2005;20:1595-602
   PubMed Web of Science ®Google Scholar
• Hjiantoniou E, Iseki S, Uney JB, Phylactou LA. DNazyme-mediated cleavage of Twist transcripts and increase in cellular apoptosis. Biochem Biophys Res Commun 2003;300:178-81
   PubMed Web of Science ®Google Scholar
• Yu X, Yang L, Cairns MJ, et al. Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme. Oncotarget 2014;5:9039-48
   PubMedGoogle Scholar
• Choi BR, Gwak J, Kwon HM, et al. Oligodeoxyribozymes that cleave beta-catenin messenger RNA inhibit growth of colon cancer cells via reduction of beta-catenin response transcription. Mol Cancer Ther 2010;9:1894-902
   PubMed Web of Science ®Google Scholar
• Sorensen DR, Leirdal M, Iversen PO, Sioud M. Combination of endostatin and a protein kinase Calpha DNA enzyme improves the survival of rats with malignant glioma. Neoplasia 2002;4:474-9
   PubMed Web of Science ®Google Scholar
• Yang L, He JT, Guan H, Sun YD. AKT1 inhibitory DNAzymes inhibit cell proliferation and migration of thyroid cancer cells. Asian Pac J Cancer Prev 2013;14:2571-5
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhao H, Shi XZ, et al. Effects of DNAzymes and siRNA targeting AKT1 on the growth of human T leukemic cells. Clin Lab 2014;60:1-8
   PubMed Web of Science ®Google Scholar
• Iversen PO, Emanuel PD, Sioud M. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukaemia cell growth. Blood 2002;99:4147-53
   PubMed Web of Science ®Google Scholar
• Yu SH, Wang TH, Au LC. Specific repression of mutant K-RAS by 10-23 DNAzyme: sensitizing cancer cell to anti-cancer therapies. Biochem Biophys Res Commun 2009;378:230-4
   PubMed Web of Science ®Google Scholar
• Xiang G, Schuster MD, Seki T, et al. Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. J Exp Med 2004;200:1657-66
   PubMed Web of Science ®Google Scholar
• Xiang G, Schuster MD, Seki T, et al. Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction. J Am Coll Cardiol 2005;46:536-41
   PubMed Web of Science ®Google Scholar
• Witkowski P, Seki T, Xiang G, et al. A DNA enzyme against plasminogen activator inhibitor- type 1 (PAI-1) limits neointima formation after angioplasty in an obese diabetic rodent model. J Cardiovasc Pharmacol 2007;50:633-40
   PubMed Web of Science ®Google Scholar
• Iversen PO, Nicolaysen G, Sioud M. DNA enzyme targeting TNF-alpha mRNA improves hemodynamic performance in rats with postinfarction heart failure. Am J Physiol Heart Circ Physiol 2001;281:H2211-17
   PubMed Web of Science ®Google Scholar
• Xiang G, Seki T, Schuster MD, et al. Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem 2005;280:39394-402
   PubMed Web of Science ®Google Scholar
• Benson VL, Khachigian LM, Lowe HC. DNAzymes and cardiovascular disease. Br J Pharmacol 2008;154:741-8
   PubMed Web of Science ®Google Scholar
• Bhindi R, Fahmy RG, McMahon AC, et al. Intracoronary delivery of DNAzymes targeting human EGR-1 reduces infarct size following myocardial ischaemia reperfusion. J Pathol 2012;227:157-64
   PubMed Web of Science ®Google Scholar
• Rayner BS, Figtree GA, Sabaretnam T, et al. Selective inhibition of the master regulator transcription factor egr-1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction. J Am Heart Assoc 2013;2:e000023
   Google Scholar
• Luo X, Cai H, Ni J, et al. c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2009;29:1836-42
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo C, Wang R, et al. An Egr-1-specific DNAzyme regulates Egr-1 and proliferating cell nuclear antigen expression in rat vascular smooth muscle cells. Exp Ther Med 2013;5:1371-4
   Web of Science ®Google Scholar
• Liu C, Zhang X, Wang S, et al. Transfected early growth response gene-1 DNA enzyme prevents stenosis and occlusion of autogenous vein graft in vivo. Biomed Res Int 2013;2013:310406
   Google Scholar
• Li Y, Bhindi R, Deng ZJ, et al. Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). Int J Cardiol 2013;168:3659-64
   PubMed Web of Science ®Google Scholar
• Sun LQ, Cairns MJ, Gerlach WL, et al. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J Biol Chem 1999;274:17236-41
   PubMed Web of Science ®Google Scholar
• Xie J, Zhang S, Hu Y, et al. Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation. Biochim Biophys Acta 2014;1842:2479-88
   PubMed Web of Science ®Google Scholar
• Chaudhury I, Raghav SK, Gautam HK, et al. Suppression of inducible nitric oxide synthase by 10-23 DNAzymes in murine macrophage. FEBS Lett 2006;580:2046-52
   PubMed Web of Science ®Google Scholar
• Verma N, Tripathi SK, Chaudhury I, et al. iNOS-targeted 10-23 DNAzyme reduces LPS-induced systemic inflammation and mortality in mice. Shock 2010;33:493-9
   PubMed Web of Science ®Google Scholar
• Isaka Y, Nakamura H, Mizui M, et al. DNAzyme for TGF-beta suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 2004;66:586-90
   PubMed Web of Science ®Google Scholar
• Sel S, Wegmann M, Dicke T, et al. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol 2008;121:910-16; e915
   PubMed Web of Science ®Google Scholar
• Turowska A, Librizzi D, Baumgartl N, et al. Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. Toxicol Appl Pharmacol 2013;272:365-72
   PubMed Web of Science ®Google Scholar
• Press releases. Available from: http://www.sterna-biologicals.com/press-releases/? [Last accessed 14 May 2014]
   Google Scholar
• Grimpe B, Silver J. A novel DNA enzyme reduces glycosaminoglycan chains in the glial scar and allows microtransplanted dorsal root ganglia axons to regenerate beyond lesions in the spinal cord. J Neurosci 2004;24:1393-7
   PubMed Web of Science ®Google Scholar
• Hurtado A, Podinin H, Oudega M, Grimpe B. Deoxyribozyme-mediated knockdown of xylosyltransferase-1 mRNA promotes axon growth in the adult rat spinal cord. Brain 2008;131:2596-605
   PubMed Web of Science ®Google Scholar
• Grassi G, Grassi M. First-in-human trial of Dz13 for nodular basal-cell carcinoma. Lancet 2013;381:1797-8
   PubMed Web of Science ®Google Scholar
• Cao Y, Yang L, Jiang W, et al. Therapeutic evaluation of epstein-barr virus-encoded latent membrane protein-1 targeted DNAzyme for treating of nasopharyngeal carcinomas. Mol Ther 2014;22:371-7
   PubMed Web of Science ®Google Scholar
• Homburg U, Turowska A, Kuhlmann J, et al. Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects. Euro Respir J 2013;42(Suppl 57):4858
   Google Scholar
• Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-4
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11
   PubMed Web of Science ®Google Scholar
• Pecot CV, Calin GA, Coleman RL, et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011;11:59-67
   PubMed Web of Science ®Google Scholar
• Vickers TA, Koo S, Bennett CF, et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003;278:7108-18
   PubMed Web of Science ®Google Scholar
• Birmingham A, Anderson EM, Reynolds A, et al. 3’ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006;3:199-204
   PubMed Web of Science ®Google Scholar
• Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006;12:1179-87
   PubMed Web of Science ®Google Scholar
• Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008;19:111-24
   PubMed Web of Science ®Google Scholar
• Kenski DM, Butora G, Willingham AT, et al. siRNA-optimized modifications for enhanced in vivo activity. Mol Ther Nucleic Acids 2012;1:e5
   PubMedGoogle Scholar
• Kubowicz P, Zelaszczyk D, Pekala E. RNAi in clinical studies. Curr Med Chem 2013;20:1801-16
   PubMed Web of Science ®Google Scholar